Skip to content
Vivo logo
← All articles

Longevity Biomarkers: What They Measure and What They Can't Tell You

Longevity Biomarkers: What They Measure and What They Can’t Tell You

Abstract illustration of multiple aging measures

Longevity biomarkers are measurable indicators of how well the body is aging, from blood chemistry and grip strength to DNA methylation patterns. Some have strong evidence behind them, some are still research tools, and none can tell you how long you will live. This guide explains the main categories, how longevity blood tests fit in, what biological-age scores can and cannot support, and what to check before paying for a testing or treatment subscription.

Vivo ClinicPut Biomarker Results in ContextVivo Clinic offers provider-supervised, personalized treatment selection, with therapies prepared by licensed U.S. pharmacies and delivered to your door.Explore Vivo Clinic

TL;DR

  • A biomarker of aging is a quantitative measure that predicts biological age and, ideally, changes when an intervention works. It is not a diagnosis.
  • Physical function (cardiorespiratory fitness, strength, gait) and routine blood chemistry currently have more established predictive value than most molecular aging clocks.
  • No single marker predicts mortality better than a composite. Trends across several markers, interpreted by a licensed provider, are more informative than any one number.
  • There are no trials showing that lowering an epigenetic age score improves morbidity or mortality, so treat those scores as context, not a goal.

Table of Contents

What longevity biomarkers are

A 2023 review in Cell defines a biomarker of aging as a quantitative parameter that predicts biological age. Biological age, in turn, is a summary of age-related biological change, distinct from chronological age, which is simply years since birth. The same review adds that a useful aging biomarker should reflect the varied biological processes underlying aging and, ideally, respond to interventions aimed at aging.

Three terms are often blurred together:

  • Longevity biomarker: any measurable indicator linked to aging processes or to long-term outcomes such as frailty, disease or mortality.
  • Biological-age test: a model, often called a clock, that combines one type of measurement (DNA methylation, routine blood values, metabolites) into a single estimate of age.
  • Routine screening: standard tests used to detect or monitor specific conditions, such as lipid panels for cardiovascular risk or HbA1c for diabetes. Many of the most useful longevity markers are in fact these tests, read over time.

The distinction matters because a biological-age number can feel authoritative while resting on a narrower evidence base than a cholesterol or glucose result that has decades of clinical use behind it.

Chronological versus biological age

Two people at 50 can differ in cardiovascular fitness, metabolic health and inflammation. Biological age tries to capture that difference. Lifestyle factors that influence it, such as sleep, activity, stress and heat exposure, are an active research area; for one example of how recovery habits are discussed alongside aging, see this overview of sauna use and longevity.

The main categories of longevity biomarkers

A 2022 academic review of biological age predictors describes candidate markers spanning physical function, routine clinical chemistry, inflammation, metabolism, kidney function, telomeres, DNA methylation and other molecular measures. Because aging is multidimensional and single markers are often nonspecific, studies frequently use composite panels.

Category Examples Typical way it is measured Maturity of evidence
Physical function Cardiorespiratory fitness (VO2 max), grip strength, gait speed Exercise test, dynamometer, timed walk Strongest links to morbidity and mortality
Routine clinical chemistry Lipids and apolipoproteins, HbA1c, glucose, kidney function Blood draw at a certified lab Established in clinical practice
Inflammation hs-CRP and related markers Blood draw Used clinically; interpretation depends on context
Epigenetic clocks DNA methylation age, pace of aging Blood sample, specialized assay Research-grade; limited clinical use
Metabolomic scores Multi-metabolite mortality scores Blood sample, specialized assay Research-grade
Telomere length Leukocyte telomere length Blood sample Variable; high measurement noise

Physical markers come first

In a 2025 npj Aging paper, Regula Furrer and Christoph Handschin argue that physiological biomarkers currently have clear advantages over molecular ones: they give direct readouts of multi-organ health and can be changed by interventions. Cardiorespiratory fitness, measured as maximal oxygen uptake, and functional tests presently show stronger predictive value for morbidity and mortality in humans than molecular aging markers do.

For people with consistent workout routines, this is useful. A VO2 max estimate from a wearable, a strength benchmark or a timed walk is not a substitute for laboratory work, but it belongs in the same record.

Molecular markers and aging clocks

Public datasets show how broad this field is. The CDC’s National Center for Health Statistics documents blood DNA-methylation biomarkers in NHANES that predict chronological age, phenotypic age, telomere length, pace of aging, mortality and mitotic cell turnover. These are research variables for population studies, not clinical decision tools.

Clocks also disagree. In two cohorts, the mortality-trained DNAm GrimAge clock and the MetaboHealth metabolomic score were each associated with frailty and mortality, yet they captured different aspects of aging. Two different tests can therefore return different answers for the same person without either being wrong.

Why no single biomarker settles the question

A frequent search is for the single best predictor of longevity. The evidence points to a composite. A 2024 GeroScience analysis from Canada found that no individual biomarker predicted mortality better than the Frailty Index; Frailty Index scores outperformed each of the 70 biomarkers examined. The authors advocate routine Frailty Index assessment in clinical settings instead of reliance on solitary markers.

The practical reading:

  • A single abnormal value is a prompt for a conversation, not a verdict.
  • A single normal value is not reassurance about everything else.
  • Direction over time, across several systems, carries more information than one snapshot.

What longevity blood tests typically cover

Longevity blood tests are usually bundles of conventional laboratory measurements, sometimes with an add-on epigenetic or specialty assay. Panels commonly group markers by system:

  • Metabolic: fasting glucose, HbA1c, and sometimes fasting insulin.
  • Cardiovascular: lipid panel, with apolipoprotein B and lipoprotein(a) added in more extensive panels.
  • Inflammation: high-sensitivity C-reactive protein (hs-CRP).
  • Organ function: liver enzymes, kidney markers such as creatinine and eGFR, and a complete blood count.
  • Hormonal and nutritional: thyroid markers, vitamin D, B12 and, depending on sex and age, sex hormones.

The exact content differs by provider, and panels are not standardized, so compare line by line rather than by the name of the bundle.

Interpreting and retesting

Reference ranges describe a laboratory population, not an individual target. Three habits make results more useful:

  1. Keep conditions consistent. Fasting status, time of day, recent hard exercise, illness and alcohol can all shift values. Draw samples under similar conditions each time.
  2. Retest to confirm a change. One out-of-range value, particularly a borderline one, is often repeated before anything is concluded.
  3. Review with a licensed clinician. Medication, family history and symptoms change what a number means. Anyone with a very high or very low result, or with symptoms, should contact a physician rather than wait for the next scheduled panel.

How often to retest depends on the marker and the clinical question, and is a decision for the treating provider. Wearable data such as resting heart rate, heart rate variability and sleep can be added to the record, with the understanding that consumer devices estimate rather than diagnose.

What biological-age scores cannot do yet

A 2022 clinical commentary on age-based screening guidelines states that blood-based epigenetic age should not replace existing screening tests. It cites several barriers to clinical adoption: different clocks, uncertain reference ranges, cost, and the absence of trials proving that changing epigenetic age improves morbidity or mortality. The authors say studies should show that guidelines updated with biological age actually improve cancer detection and patient outcomes before those guidelines change.

For a consumer, this translates into three cautions:

  • A younger-than-chronological score is not proof of good health, and an older score is not a diagnosis.
  • Moving a score through a supplement or therapy does not by itself show a health benefit.
  • Scores from different clocks should not be compared with one another.

Does aging happen at a particular age?

Readers often ask at what age people age most rapidly. We did not find a checked, authoritative source that fixes a single age, and the research above emphasizes that aging is multidimensional, with different systems changing on different timelines and at different speeds in different people. Individual trajectories from your own repeated measurements are more informative than a population average.

Individual aging paths diverge from a population average

Questions to ask before buying a longevity subscription

Subscriptions that bundle lab testing, dashboards, supplements or prescriptions vary widely. Before paying, check:

  • Who reviews results. Is a licensed clinician reading your panel and available to answer questions, or is it an automated report?
  • Where samples are processed. Look for the type of laboratory and what it is certified to do.
  • What is actually measured. Compare the marker list, not the marketing name.
  • What happens next. A result that suggests a prescription should lead to a provider evaluation, not an automatic product recommendation.
  • How data is handled. Ask whether health information is covered under HIPAA-compliant practices, who can see it, and whether it is shared or sold.
  • Total cost over a year. Include retesting, supplements and any required membership.

Our perspective

We see two common mistakes among people who track longevity biomarkers. The first is treating one score, especially a biological-age estimate, as an objective of its own. The evidence we reviewed does not support that: physical function and a spread of conventional markers have the firmest footing, and no trial has shown that shifting an epigenetic clock improves outcomes.

Our perspective — overview diagram

The second is moving directly from a number to a product. At Vivo Clinic, the process runs the other way. A licensed provider reviews your history and goals, treatment selection is guided and individualized, and prescriptions are compounded by licensed U.S. pharmacies and delivered to your home, with ongoing medical oversight and HIPAA-compliant handling of your data. Not every patient is a candidate for every therapy, and a provider may decline to prescribe.

We also keep claims narrow. Our therapies are not presented as treatments that lower a biological-age score or extend life, and the research on several of them is still developing. For context on the state of the evidence, see our overview of peptides for longevity.

— Jack

Where a telehealth provider fits

If your lab work, wearable data and goals lead you to consider a prescription therapy, a telehealth provider can evaluate whether it is appropriate without an in-office visit. That suits busy professionals, frequent travelers and people far from a longevity clinic. Vivo Clinic offers provider-supervised, compounded options at the following published monthly prices:

Plan Price
NAD+ Nasal Spray $129 per month
Glutathione Nasal Spray $149 per month
Sermorelin $139 per month
MIC+B12 $119 per month
NAD+ Face Cream $129 per month
Tirzepatide & Semaglutide $199 per month

NAD+ is also available as a prescription injection. Start at vivoclinic.org to begin the intake; approval and treatment selection depend on provider review.

A practical way to start tracking

  1. Record function. Note a fitness estimate, a strength benchmark and a walking-speed or similar test.
  2. Get a conventional panel. Metabolic, lipid, inflammation and organ-function markers, drawn under consistent conditions.
  3. Review with a clinician. Bring family history, medications and symptoms.
  4. Change one thing at a time. Whether sleep, training or a prescribed therapy, a single change makes the next result easier to interpret.
  5. Retest on a schedule your provider sets. Look at direction across markers, not one value.

FAQ

What are the best biomarkers to track for longevity?

The best-supported are physical function measures such as cardiorespiratory fitness and strength, plus routine blood markers for metabolic, cardiovascular and inflammatory health. Research shows no single marker outperforms a composite such as the Frailty Index, so panels read over time are more useful than one value.

Can a blood test tell me my biological age?

Some tests estimate it using DNA methylation or routine blood values, but different clocks can give different results for the same person. Commentary in the medical literature says these scores should not replace existing screening tests, and no trials show that changing the score improves health outcomes.

How often should I repeat longevity blood tests?

The interval depends on the marker, your results and your health history, so it is set with a licensed clinician. A borderline result is commonly repeated under similar conditions, such as the same fasting status and time of day, to confirm it.

Do I need a prescription therapy to improve my biomarkers?

No. Many conventional markers respond to sleep, activity, nutrition and medical management of specific conditions. Prescription therapies are an option only after a provider evaluates your history, and they are not proven to change aging scores.

Sources